Generated by AI
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer. Its research approach combines pelareorep with chemotherapy and immune checkpoint inhibitors to improve how tumors respond to treatment. Oncolytics Biotech also advances clinical studies and regulatory development efforts through its pipeline and strategic collaborations, positioning the company within the oncology immunotherapy market.
Website4350 Executive Drive
San Diego, CA, 92121
United States
The latest articles about ONCY.
Announced translational data in heavily pretreated relapsed/refractory multiple myeloma patients, which ...
Announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination ...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy 100% of responding patients survived for longer than one year FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Co
Summary of Aug 19's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about ONCY also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.